You're asking about a specific chemical compound with a complex name: **1-(4-methyl-1,3-benzothiazol-2-yl)-3-[3-(methylthio)phenyl]urea**.
Let's break down what it is and why it might be important in research:
**Structure and Properties:**
* **1-(4-methyl-1,3-benzothiazol-2-yl)-3-[3-(methylthio)phenyl]urea** is an organic compound. Its structure features:
* **A benzothiazole ring:** A six-membered ring containing both benzene and thiazole components. The 4-methyl indicates a methyl group attached at the 4th position on this ring.
* **A urea group:** A functional group with the structure (NH2)2CO.
* **A phenyl group:** A benzene ring. The 3-(methylthio) part indicates that a methylthio group (CH3S-) is attached at the 3rd position on this phenyl ring.
**Potential Importance in Research:**
While the compound itself is not widely known or studied, its structure and components suggest potential applications in research areas such as:
* **Pharmacology:** The benzothiazole ring is known to be present in various pharmacologically active molecules, including anti-inflammatory agents, antimicrobials, and antihypertensives. The urea group is often associated with drugs targeting enzymes or receptors. The methylthio group can influence the compound's biological activity.
* **Materials Science:** The combination of aromatic rings (benzothiazole and phenyl) could contribute to interesting properties in materials, such as conductivity or optical behavior.
* **Organic Chemistry:** This compound could be used as a starting point for the synthesis of new molecules with specific functionalities.
* **Chemical Biology:** Studying how this compound interacts with biological systems (cells, proteins, etc.) could provide insights into the role of the individual components (benzothiazole, urea, phenylthio) in biological processes.
**Finding More Information:**
To learn more about this specific compound and its potential applications, you'll need to do some research.
* **Chemical Databases:** Check databases like PubChem, SciFinder, or Reaxys to see if any information is available on this specific compound.
* **Scientific Literature:** Search for relevant scientific publications (articles, patents) using keywords related to the structure and potential applications mentioned above.
* **Expert Consultation:** If you need more in-depth information, you could consult with experts in organic chemistry, medicinal chemistry, or related fields.
**Important Note:** The importance of a compound is not determined solely by its structure. The significance often depends on its specific properties, how it interacts with other molecules, and its potential use in solving real-world problems.
ID Source | ID |
---|---|
PubMed CID | 332435 |
CHEMBL ID | 1359306 |
CHEBI ID | 115070 |
Synonym |
---|
mls000758507 , |
nsc329255 |
nsc-329255 |
smr000528948 |
CHEBI:115070 |
1-(4-methyl-1,3-benzothiazol-2-yl)-3-(3-methylsulfanylphenyl)urea |
CHEMBL1359306 |
Q27196914 |
1-(4-methyl-1,3-benzothiazol-2-yl)-3-[3-(methylthio)phenyl]urea |
Class | Description |
---|---|
ureas | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
TDP1 protein | Homo sapiens (human) | Potency | 14.9692 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 3.5481 | 0.1800 | 13.5574 | 39.8107 | AID1468 |
67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 3.5481 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 89.1251 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 79.4328 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 100.0000 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 2.2387 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |